Dedicated researchers convinced of a crucial role for biomedical science to overcome drug resistance in cancer treatments

Developing novel biologics for tackling novel challenges

You need reliable molecular tools to perform efficient preclinical drug candidate selection to ensure success in clinical trials of cancer therapeutics. We design and develop novel molecular indicators that allow the monitoring of the drug potentials to induce resistance and fibrotic extracellular matrix synthesis.

We develop and provide the community with novel biologics to tackle the challenge of defining the spatial arrangement and physical properties of the extracellular matrix proteins synthesized under the treatment with drug candidates. This is singular to our designed biologics compared to commonly used tools such as nanoparticles and antibodies that are bigger in size with less penetration in dense stromal tissue structures. Although antibodies recognize exposed sequences and conformations allowing quantification of extracellular matrix proteins, they present limited capacity in identifying the strain distribution as well as the particular arrangement of early fibrotic fibers.

By assembling our expertise in protein engineering, extracellular matrix biology, fibrosis and cancer therapy, we commit in developing the tools needed to make preclinical studies efficient, and proposing novel therapeutic approaches that mitigate the drug-induced resistance during cancer treatment.